



Bring No-charge Genetic Counseling and Testing to Your Patients with Sensorineural Hearing Loss



More than 60% of congenital hearing loss is due to an underlying genetic cause¹⁻²

The Resonate® program uses a comprehensive panel of nearly 300 genes to potentially determine whether there is an underlying genetic cause of hearing loss.

Eligibility


Individuals under 40 years of age in the U.S. with at least one of the following:

- Bilateral or unilateral sensorineural hearing loss (by auditory brainstem response or behavioral testing) of mild, moderate, moderately severe, severe, or profound degree
- Auditory neuropathy

Simple Ordering Process


Healthcare providers can order directly or refer patients to genetic counselors at InformedDNA who can provide the following at no charge:

- Pre-test genetic counseling
- Test ordering and sending the sample collection kit to the patient's home
- Post-test counseling




Easy

- Specimen collection via cheek swab, saliva, or blood draw
- Kits can be sent to your office or patient's home



Fast

- Results will usually be available within 3 to 4 weeks of receiving the sample



No Cost

- No cost to the patient, their insurance, or their healthcare providers



Test Today

Genetic testing, using a comprehensive gene panel, is recommended as a critical part of the diagnostic workup for sensorineural hearing loss^{1,3-4}



Diagnose Early

Genetic testing may allow for early diagnosis of syndromic conditions⁵ and may provide information about hearing loss progression⁶ and inheritance risk⁷



Inform Care

A genetic diagnosis may help personalize patient care by guiding treatment decisions,⁸ communication options,⁹ and potential eligibility for gene therapy clinical trials⁷

How to order

- Providers (including audiologists) may refer patients for genetic test ordering and pre- and post-test counseling: referrals.informedna.com/akouos-resonate
- To order sample collection kits, genetic testing, and optional genetic counseling (for providers with experience ordering genetic services): akouosresonate.preventiongenetics.com
- To learn more: AkouosResonate.com



Resonate is sponsored by Eli Lilly and Company. Lilly is committed to the development of novel genetic medicines. Lilly partners with **InformedDNA** and **PreventionGenetics** to offer the Resonate program.

Your privacy is important. No patient personal identifiable information will be shared with Eli Lilly and Company. Healthcare providers' names and contact information along with de-identified patient information may be shared with Lilly as part of this program. For more information about your privacy, visit AkouosResonate.com.

References: **1.** Shearer AE, Hildebrand MS, Odell AM, et al. Genetic hearing loss overview. 1999 Feb 14 [Updated 2025 Apr 3]. In: Adam MP, Bick S, Mirzaa GM, et al, eds. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1434/> **2.** Morton CC, Nance WE. Newborn hearing screening—a silent revolution. *N Engl J Med*. 2006;354(20):2151-2164. **3.** Liming BJ, Carter J, Cheng A, et al. International Pediatric Otolaryngology Group (IPOG) consensus recommendations: hearing loss in the pediatric patient. *Int J Pediatr Otorhinolaryngol*. 2016;90:251-258. **4.** Li MM, Tayoun AA H, DiStefano M, et al. Clinical evaluation and etiologic diagnosis of hearing loss: a clinical practice resource from the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2022;24(6):1392-1406. **5.** Vona B. Rethinking non-syndromic hearing loss and its mimics in the genomic era. *Eur J Hum Genet*. 2025;33(2):147-150. **6.** Carlson RJ, Merrill AE, Malloy AM, et al. Association of genetic diagnoses for childhood-onset hearing loss with cochlear implant outcomes. *JAMA Otolaryngol Head Neck Surg*. 2023;149(3):212-222. **7.** Shearer AE. Genetic testing for pediatric sensorineural hearing loss in the era of gene therapy. *Curr Opin Otolaryngol Head Neck Surg*. 2024;32(5):352-356. **8.** Brewer CC, King KA. Genetic hearing loss: the audiologist's perspective. *Hum Genet*. 2022(141):311-314. **9.** Eshraghi AA, Polineni SP, Davies C, et al. Genotype-phenotype correlation for predicting cochlear implant outcome: current challenges and opportunities. *Front Genet*. 2020;11:678.



Resonate® is a trademark owned by Eli Lilly and Company. ©2026 Eli Lilly and Company. All rights reserved. MMAT-05457 06/2026